A212102 evaluates a blinded reference set for multicancer early-detection blood tests to measure accuracy and control false positives, with breast cancer included.

The Alliance is advancing clinical trials focused on de-escalation and survivorship, including treatment pauses after pathologic complete response in early-stage TNBC, shortened adjuvant therapy for HER2-positive breast cancer, and telehealth-guided exercise to preserve function during chemotherapy.

Survivor-focused projects include Revitalize, testing fractional CO2 laser therapy for vaginal atrophy, and Project Reach, a text-based smoking cessation program for rural cancer survivors.

The Alliance highlights its extensive impact and leadership in cancer research, stressing recognition of patients, survivors, families, advocates, clinicians, and researchers, along with a vast biospecimen repository and broad guideline influence.

Its reach spans more than 26,000 cancer specialists across 112 institutions and 1,400 affiliated sites in the US and Canada, with over 40,000 participants and a biospecimen repository containing around 1.5 million samples.

A221801 Revitalize specifically evaluates fractional CO2 laser therapy to relieve vaginal dryness/atrophy in breast cancer survivors and improve quality of life after treatment.

A211901 Project Reach assesses a scalable, text-based smoking cessation intervention tailored for rural cancer survivors.

Mortality among women has declined by about 44% since 1989, reflecting progress from early detection and treatment improvements driven by clinical trials.

The Alliance aims to advance prevention, early detection, treatment optimization, survivorship, and personalized care through a diverse, patient-centered trial portfolio.

Breast cancer remains the most common cancer among women, with estimated U.S. cases and deaths for 2026 reflecting ongoing impact across sexes, including a small number of male cases.

The AYA Access Study pilots an enhanced at-home genetic counseling/testing model with eHealth tools and chatbot support to improve access for adolescents and young adults with a cancer history.

This prevention/early-detection emphasis includes multicancer early detection tests and a broader eHealth/genetic services delivery model to expand access to genetic risk information for young people with cancer history.